ONCOLOGUES - Trademark Details
Status: 645 - Final Refusal - Mailed
Serial Number
88900007
Word Mark
ONCOLOGUES
Status
645 - Final Refusal - Mailed
Status Date
2021-07-28
Filing Date
2020-05-04
Mark Drawing
4000 - Standard character mark
Typeset
Attorney Name
Law Office Assigned Location Code
N30
Employee Name
KEAN, AMY C
Statements
Goods and Services
Pharmaceutical and medicinal preparations for the treatment of cancer and oncological conditions; Pharmaceuticals, namely, drug delivery agents in the form of compounds that facilitate delivery of injectable pharmaceutical preparations and in the form of subcutaneous compounds that provide controlled release, and in the form of injectable pharmaceuticals, powders, tablets, capsules, pills, caplets, liquid drops, sachets, spray, ointment, cream, gel, lotion, patch, inhaler, granule, film, suspension, infusion and suppository, capsules, and tablets of peptide nucleic acids for the treatment of cancer and oncological conditions; Oncological preparations, namely, pharmaceutical preparations for the detection, prevention, and treatment of cancer; Pharmaceutical and medicinal preparations for the treatment of cancer, cell transplants and cell transplant rejection, organ transplants and organ transplant rejection, angiogenesis, bacterial infection, peripheral blood stem cell mobilization, lymphoma, tissue regeneration, tissue repair, leukemia, drug-induced anemia, retrovirus, viral infections, hematopoietic deficit resulting from chemotherapy or radiation therapy, elevation of white blood cells; Stem cells for medical purposes; Synthetic peptides for the treatment of cancer and oncological conditions; Biological tissue cultures for medical purposes; Therapeutic products, namely, antibodies, proteins and peptide therapeutics for treating cancer and oncological conditions; Vaccine preparations; Medical assays for testing of body fluids
Goods and Services
Pharmaceutical product development services; Pharmaceutical product evaluation services; Pharmaceutical research and development; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development of pharmaceuticals for the treatment of cancer and oncological conditions; Research and development of vaccines and medicines; Technical research in the field of pharmaceutical studies; Development of computer platform technology, namely, development of cancer immunotherapy software platforms for manufacturing therapeutics; Consulting services for others in the field of design, planning, and implementation of clinical trials; Information technology platform as Service (PaaS) featuring computer software platforms for cancer diagnosis and analysis of cancer symptoms and cancer treatment, in the medical field; Electronic data storage; Providing a bioinformatics platform as a service (PAAS) featuring computer software platforms for sequence data analysis in the field of manufacturing therapeutics; Medical and scientific research information in the field of cell therapy; Scientific research and analysis for medical purposes in the field of cancer, oncology and clinical trials
Classification Information
International Class
042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services. - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services.
US Class Codes
100, 101
Class Status Code
6 - Active
Class Status Date
2020-05-15
Primary Code
042
First Use Anywhere Date
2020-05-00
First Use In Commerce Date
2020-05-00
Current Trademark Owners
Party Name
Party Type
10 - Original Applicant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Devon E. White
Address
Please log in with your Justia account to see this address.
Trademark Events
Event Date | Event Description |
2020-05-07 | NEW APPLICATION ENTERED IN TRAM |
2020-05-15 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2020-07-29 | ASSIGNED TO EXAMINER |
2020-08-04 | NON-FINAL ACTION WRITTEN |
2020-08-04 | NON-FINAL ACTION E-MAILED |
2020-08-04 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2021-02-03 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2021-02-03 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2021-02-03 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2021-06-21 | ASSIGNED TO EXAMINER |
2021-07-28 | FINAL REFUSAL WRITTEN |
2021-07-28 | FINAL REFUSAL E-MAILED |
2021-07-28 | NOTIFICATION OF FINAL REFUSAL EMAILED |
2022-01-26 | TEAS AMENDMENT OF USE RECEIVED |
2022-01-27 | USE AMENDMENT FILED |
2022-01-27 | AMENDMENT TO USE PROCESSING COMPLETE |
2022-01-27 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
2022-01-27 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2022-01-27 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2022-02-11 | USE AMENDMENT ACCEPTED |
2022-02-12 | NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED |